Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD by Cazzola, Mario et al.
lable at ScienceDirect
Pulmonary Pharmacology & Therapeutics 31 (2015) 68e78Contents lists avaiPulmonary Pharmacology & Therapeutics
journal homepage: www.elsevier .com/locate/ypuptAssessing the clinical value of fast onset and sustained duration of
action of long-acting bronchodilators for COPD
Mario Cazzola a, *, Kai M. Beeh b, David Price c, Nicolas Roche d
a Unit of Respiratory Clinical Pharmacology, Department of Systems Medicine, and Postgraduate School of Respiratory Medicine, University of Rome ‘Tor
Vergata’, Via Montpellier 1, 00133, Rome, Italy
b Insaf Respiratory Research Institute, Biebricher Allee 34, D-65187 Wiesbaden, Germany
c Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Aberdeen AB25 2ZD, UK
d Service de Pneumologie AP-HP, University Paris Descartes (EA2511), Groupe Hospitalier Cochin, HIA du Val de Gra^ce 4e C, 74 Bd de Port Royal,
F-75005 Paris, Francea r t i c l e i n f o
Article history:
Received 27 October 2014
Received in revised form
9 February 2015
Accepted 12 February 2015
Available online 26 February 2015
Keywords:
Adherence
Beta-2 adrenergic agonists
Chronic obstructive pulmonary disease
Long-acting bronchodilators
Muscarinic antagonists
Onset of action* Corresponding author. Tel.: þ39 348 6412311.
E-mail addresses: mario.cazzola@uniroma2.it (M.
(K.M. Beeh), dprice@rirl.org (D. Price), nicolas.roche@
http://dx.doi.org/10.1016/j.pupt.2015.02.007
1094-5539/© 2015 Published by Elsevier Ltd.a b s t r a c t
The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease
(COPD) vary in their pharmacological class (b2-adrenergic agonist or antimuscarinic/anticholinergic,
alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of
development of a maintenance bronchodilator, the goals are to identify a molecule with the theoretically
‘ideal’ proﬁle of fast onset and prolonged duration of action in comparison with existing agents, while
minimizing non-speciﬁc activity at organs outside the lungs. The move towards increasing duration of
bronchodilator action is generally paralleled by improved effects on clinical outcomes, and the advent of
more potent agents seems likely to provide an opportunity to reduce overreliance on the use of inhaled
corticosteroids in treating COPD. In terms of onset of action, an immediately perceived beneﬁt in
reducing dyspnea, although not deﬁnitively demonstrated, might prove useful in increasing adherence,
which is very poor among patients with COPD. Once-daily administration may also be helpful in this
respect. Shared decision-making between patient and physician in the choice of treatment is important
in optimizing adherence and, thus, treatment effectiveness.
© 2015 Published by Elsevier Ltd.1. Introduction
Pharmacological treatment of chronic obstructive pulmonary
disease (COPD) is used to improve lung function, thereby alleviating
symptoms, reducing exacerbations and improving health status
and exercise tolerance [1]. These aims hold true for each of the
main treatment options available, namely long-acting bronchodi-
lators (long-acting b2-adrenergic agonists [LABA] and long-acting
muscarinic antagonists [LAMA]), inhaled corticosteroids (ICS;
used only in combination with b2-adrenergic agonists for COPD)
and the various combinations of these agents. In the treatment of
COPD, inhaled long-acting bronchodilators provide effective treat-
ment against the outcomes listed above, including exacerbations
and exercise tolerance, through mechanisms of increased airwayCazzola), k.beeh@insaf-wi.de
cch.aphp.fr (N. Roche).patency and reduced hyperinﬂation [2,3]. While no treatment has
been proven conclusively to reduce the accelerated decline in lung
function that characterizes COPD, post-hoc analyses have reported
a slower loss of lung function during treatment with long-acting
bronchodilators and ICS/LABA combinations, compared with pla-
cebo, in patients with moderate-to-severe COPD [4,5].
Characteristics of an ideal new bronchodilator should include
longer duration of action, with at least a 24-h sustained broncho-
dilator effect allowing once-daily dosing, a fast onset of broncho-
dilator action at least similar to that of salbutamol (thusminimizing
undue reliance on rescue medication), and a favorable safety and
tolerability proﬁle [6]. An increasing number of long-acting bron-
chodilators have become available in recent years. Their efﬁcacy
has generally advanced in line with increasing duration of action
(short-to long-acting [7]; twice-to once-daily [8,9]) and potency of
bronchodilation (mono-to combination therapy [10]), without any
added safety concerns [7e9,11].
Given the current or imminent availability of several long-acting
bronchodilators for use in patients with COPD, is it important or
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the onset and duration of action of long-acting bronchodilators for
COPD and consider whether the theoretical ‘ideal’ proﬁle translates
into practical and clinical advantages for patients. Data on onset
and duration were obtained from a search of the literature on
PubMed for the currently used long-acting bronchodilators in
COPD (in English; no date restrictions), with preference given to
data from phase III studies using approved doses.2. Comparative pharmacological characteristics of currently
available long-acting bronchodilators
2.1. Long-acting b2-adrenergic agonists (LABAs)
b2-adrenergic receptors are present in high concentrations in
the smooth muscle of the lungs, predominantly the small airways.
They are coupled to an intracellular G-protein (Gs), which is stim-
ulated when the agonist interacts with the b2-adrenoceptor. This
sets off an intracellular signaling reaction with production of ade-
nylyl cyclase increasing cyclic adenosine monophosphate (cAMP),
leading to a fall in intracellular calcium levels, and the opening of
large-conductance potassium channels. This causes hyperpolar-
ization and relaxation of airway smooth muscle [12]. However, it
has become increasingly clear that signaling through adenylyl
cyclase-coupled pathways is considerably more complex and so-
phisticated than was considered previously, and there is still little
known regarding these pathways in airway cells [13].
Several factors determine onset of effect of LABAs after delivery
by inhalation. One is the time taken to reach effective concentra-
tions at the local receptor site, with diffusion rates determined by
physico-chemical properties of the drug molecule. The more lipo-
philic the molecule, the slower the onset; a degree of water solu-
bility, allowing rapid diffusion into intracellular spaces, is needed
for a faster onset [14,15]. High intrinsic efﬁcacy (full agonism) at the
receptor promotes a fast rate of cAMP accumulation, and this may
explain the fast onset of action of some relatively lipophilic b2-
adrenoceptor agonists [16,17]. Some pharmacological properties of
the various agents are summarized in Table 1 [18]. Formoterol and
indacaterol have similar, high intrinsic efﬁcacy at the b2-adreno-
ceptor: 95% and 86%, respectively, relative to isoprenaline (100%).
Vilanterol is somewhat lower at 70%, but still higher than salme-
terol (41%) [18]. Olodaterol is reported to have 88% intrinsic efﬁcacy
at the b2-adrenoreceptor and a potency (pEC50 ¼ 9.93) similar to
that of salmeterol (9.90) and formoterol (9.73) [19]. Potency in
electrical ﬁeld stimulated human bronchial rings (pEC50 ¼ 9.49)
was similar to that of formoterol (9.73) [19]. Preclinical studies with
olodaterol report that its onset of action is comparable to for-
moterol, with maximal bronchoprotection after inhalation of a
single dose of olodaterol or formoterol reached within 3e6 min in
guinea pigs and 10 min in dogs [19].Table 1
In-vitro characterization of b2-adrenergic agonists: potency, onset and intrinsic ef-
ﬁcacy data [18].
b2-adrenergic agonist EFS guinea pig
trachea model
cAMP detection assays
(b2-adrenoreceptor)
Potency
(pEC50)
Onset t½
(min)
Potency
(pEC50)
Intrinsic efﬁcacy
(b2)a
Vilanterol 8.62 ± 0.27 5.8 ± 0.5 10.37 ± 0.05 0.70 ± 0.03
Salmeterol 6.84 ± 0.03 15.2 ± 0.6 9.80 ± 0.10 0.41 ± 0.01
Formoterol 8.56 ± 0.18 4.0 ± 0.1 10.14 ± 0.08 0.95 ± 0.04
Indacaterol 6.84 ± 0.16 4.0 ± 0.2 9.48 ± 0.08 0.86 ± 0.02
a Relative to isoprenaline (¼1). cAMP, cyclic adenosine monophosphate; EFS,
electrical ﬁeld stimulated; pEC50, negative logarithm of the half-maximal effective
concentration; t½, half-life; ND, not determined. Data from Ref. [18].The relevance of low intrinsic efﬁcacy (partial agonist activity) is
unclear, particularly for COPD. All the b2-adrenergic agonists have
some (unwanted) activity at the b1-adrenoceptor. It has been
claimed that partial agonist activity at the b1-adrenoreceptor may
result in fewer cardiovascular side effects [19], but many other
factors such as binding kinetics are likely to be involved. If receptor
numbers are low or receptors are not working efﬁciently, a partial
agonist will have a lowermaximal effect than a full agonist andmay
even act as an antagonist in the presence of a full agonist. Partial
agonist properties do not affect bronchodilator efﬁcacy, but might
reduce the ability of that agent or a rescue bronchodilator to
reverse acute severe bronchospasm [14,20,21]. Whether the degree
of intrinsic efﬁcacy relates to tolerance or desensitization to b2-
mediated effects in long-term clinical use is unknown; again, other
factors will be important, such as receptor reserve and transduction
efﬁciency in airway smooth muscle cells [22e24].
It is unclear why LABAs are able to cause such long bronchodi-
lation, and several contrasting hypotheses have been formulated
[12]. First, the anchored binding (or exosite) hypothesis suggests
that a long lipophilic tail (e.g. of salmeterol) may bind to a region of
the b2-adrenoceptor that is apart from the active receptor site,
anchoring the drug to or near the receptor and allowing repeated
receptor activation [25]. Second, a molecule with a degree of lip-
ophilicity will provide a depot of drug at the receptor site by par-
titioning into lipid regions and cell membranes [26]. An extension
to this ‘diffusion microkinetics’ model describes partitioning of
drug into lipophilic compartments (‘lipid rafts’) on airway smooth
muscle cell membranes, where b2-adrenoceptors are in close con-
tact with signaling and effector molecules, and has been proposed
to account for the duration of action of indacaterol [27,28]. Third,
tight binding to the b2-adrenoceptor and formation of a ternary
complex with a long dissociation half-life was proposed for olo-
daterol [29], but dissociation half-life alone is unlikely to account
for duration of action [18].
2.2. Long-acting muscarinic antagonists (LAMAs)
Muscarinic antagonists are also described synonymously as
antimuscarinics or anticholinergics. These agents block the effects
of the endogenous cholinergic bronchoconstrictor acetylcholine,
thus resulting in bronchodilation. Acetylcholine acts on a family of
ﬁve G-protein-coupled muscarinic receptors (M1 to M5), of which
the M1 to M3 subtypes are expressed in the airways [30]. M1 re-
ceptors are found in parasympathetic ganglia where they facilitate
neurotransmission. M2 receptors occur presynaptically on airway
smooth muscle and downregulate acetylcholine release while
capturing released acetylcholine (autoregulation). In addition, M2
receptors on airway smooth muscle couple preferentially to the G-
protein isotype Gao/i, and function to counteract the b2-adreno-
ceptor-mediated relaxant pathway by inhibiting the generation and
accumulation of cAMP [31e33]. In the heart, M2 receptors are
present post-synaptically and mediate effects such as tachycardia
[30]. M3 receptors are expressed on airway smooth muscle, sub-
mucosal mucus glands and vascular endothelium. Pharmacological
studies have indicated that under normal conditions contraction in
both central and peripheral airways is mediated primarily by the
M3 receptor [34].
Thus, the ideal proﬁle for a LAMA for COPD management is one
in which M3 receptor blockade outweighs its activity at the M2
receptor in order to provide a favorable efﬁcacy:safety ratio [12].
The LAMAs achieve this through kinetic selectivity, whereby
dissociation from M3 receptors is slower than from M2 receptors
(see Table 2). Compared with the other LAMAs listed, glyco-
pyrronium has the most favorable ratio of M3:M2 receptor resi-
dency time, although whether the apparent advantage of
Table 2
Comparison of LAMA receptor binding: dissociation rate constants and half-lives at humanM2 andM3muscarinic receptors. (From Ref. [37], with data from a separate study on
umeclidinium and tiotropium from Ref. [38]).
M2 M3 t½ M3/M2
Koff (h1) t½ (h) Koff (h1) t½ (h)
Tiotropium [37]. 0.26 ± 0.05 2.6 0.026 ± 0.005 27 10.4
Aclidinium [37]. 0.39 ± 0.03 1.8 0.071 ± 0.01 10.7 5.9
Glycopyrronium [37]. 1.84 ± 0.1 0.37 0.11 ± 0.02 6.1 16.5
Koff (min1) t½ (min) Koff (min1) t½ (min)
Tiotropium [38]. 0.023 ± 0.008 39.2 ± 9.7 0.0026 ± 0.0003 272.8 ± 27.6 7.0
Umeclidinium [38]. 0.074 ± 0.004 9.4 ± 0.5 0.0089 ± 0.0012 82.2 ± 0.0012 8.7
Koff, rate constant of dissociation of radiolabelled antagonist; t½, residence half-life.
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ical efﬁcacy and safety remains to be established.
Receptor kinetics may also explain differences in onset of action,
in terms of time taken to achieve equilibration at the M3 receptor.
The predictions from simulated kinetic rate constants that tio-
tropium would take four to ﬁve times longer than glycopyrronium
to equilibrate with the M3 receptor at equi-effective concentrations
were conﬁrmed in the in-vitro calcium assay (glycopyrronium was
5-fold faster) and the rat tracheal strip assay (2.5-fold) [35].
However, slow dissociation from the M3 receptor does not
appear to explain fully the duration of action of the LAMAs. M3
dissociation rates of glycopyrronium and tiotropium were reduced
3-fold under physiological conditions, compared with under non-
physiological conditions, to a level that was incompatible with
their known 24-h duration of action [35]. A process of rebinding of
freshly dissociated drug was proposed with respect to these agents,
perhaps through micro-anatomical constraints at a local tissue level
that restrict the free diffusion of drug molecules away from the local
environment where the receptors are concentrated [35,36].
2.3. Combination of LABA and LAMA
A synergistic (i.e. more than additive) bronchodilator effect of a
LABA and LAMA has been demonstrated in airway preparations
in vitro and in patients with COPD [39,40]. These preliminary
studies support the scientiﬁc rationale for combining the two types
of drugs but preclinical data investigating synergy are limited and
further work is required. In theory, a synergistic effect may be
explained by removal of the bronchoconstrictor effects of acetyl-
choline by the antimuscarinic, allowing an ampliﬁed b2-adren-
ergic-agonist-induced bronchodilation [31], and also by
interactions between the post-receptor intracellular signaling
pathways for M3 and b2-adrenoreceptors, resulting in an overall
ampliﬁcation of effect [34,41]. This forms the mechanistic basis for
treating patients with COPD with a combination of bronchodilators
that have different mechanisms of action. Whether such synergism
is relevant to increasing the speed of onset or prolonging the
duration of bronchodilator effect is unknown.
3. Onset and duration of effect of long-acting
bronchodilators
Onset and duration of a bronchodilator are properties that have
not been deﬁned formally in clinical terms. Onset of effect may be
expressed in various ways, usually the earliest time at which a
signiﬁcant effect is achieved vs placebo, or the time taken to reach a
particular level of bronchodilation (e.g. 100 or 200 mL, or 12% or
15% increase from baseline). Other possibilities are time to peak
effect, or time to half-maximal effect. The effect is usually expressed
in terms of forced expiratory volume in 1 s (FEV1). Onset may also
describe a statistically or clinically signiﬁcant bronchodilator effecton day 1 of treatment, which is achieved by some of the current
long-acting bronchodilators. Most LABAs and LAMAs take about
1 week to achieve pharmacokinetic steady state (up to 2e3 weeks
with indacaterol and tiotropium), but any difference in broncho-
dilator effect between ﬁrst dose and steady state will also depend
on other factors such as the degree of accumulation of drug during
this time, and the nature of the relationship between pharmaco-
kinetic and pharmacodynamic variables [42]. Glycopyrronium
takes 1 week to achieve pharmacokinetic steady state but phar-
macodynamically achieves its full bronchodilator effect after the
ﬁrst dose [43e45] (see Table 3).
Duration of effect and dosing interval or frequency (e.g. once or
twice daily) are not necessarily the same but are closely interre-
lated and are a function of maintenance dose and pharmacoki-
netics. The development of the once-daily bronchodilators
reviewed here had from the outset the aims of designing a mole-
cule with long-acting bronchodilating properties that would prove
suitable for once-daily dosing, with initial clinical studies con-
ﬁrming safety, tolerability and pharmacokinetics. Dose-ranging
clinical studies, usually measuring lung function, were then
employed to establish the minimum effective doses given once- or
sometimes twice-daily [46]. Duration of effect can be dose-
dependent [47]. Aclidinium was originally investigated as a once-
daily drug given at doses of 200 or 400 mg but was found to be
suboptimal in terms of effect size and duration; 400 mg twice daily
showed greater efﬁcacy than the 200 mg dose and this regimenwas
approved for use [48]. Regulatory perspectives on what constitutes
a minimum effective dose may vary, resulting in the approval of
different doses and regimens of a given drug at different times and
in different regions; for example, indacaterol is approved at a once-
daily dose of 75 mg in the USA and at doses of 150 and 300 mg in
other countries. On the other hand, the older drug formoterol,
introduced in 1990, was approved for use twice daily, yet its
bronchodilator effect may last for only 6 or 8 h post-dose [49].
In clinical drug trials in COPD, duration of bronchodilator effect
may be the length of time post-dose during which a statistically
signiﬁcant and/or clinically important bronchodilator effect on
FEV1 in relation to placebo is maintained, either in absolute terms
or as relative change from baseline. A 100mL difference in pre-dose
or trough FEV1 has been reported as the minimum clinically
important difference that is perceptible to patients [50]. Broncho-
protection is often used as a measure of duration of effect in
asthma, but has no corollary in COPD.
Bothonset anddurationare typically assessed in termsof changes
over time in FEV1, which is widely used, easy to measure, and a
required variable in regulatory clinical drug trials. In the specialized
setting, a more comprehensive assessment of bronchodilator effects
can be obtained using sensitive methods such as oscillometry and
body plethysmography [51]. FEV1 may be insensitive to some
important physiological abnormalities in COPD, such as hyperinﬂa-
tion [52]. However, the relevant measures of lung volume require
Table 3
Onset of bronchodilator effect.
FEV1 difference vs placebo
at 5 min post-dose (mL)a
Other onset variable (time is post-dose)a Ref.
SABAs Salbutamol 200 mg 90 (95% CI 60, 120) 7.9% (95% CI 5.5, 10.3) increase at 5 min vs placebo
36% of patients with 12% increase at 5 min vs baseline
23% of patients with 12% and >200 mL increase from
baseline
[56]
Twice-daily LABAs Formoterol 12 mg 140 (95% CI 120, 160) [57]
e 10% decrease of Raw at 1.4 ± 0.9 min [58]
e 7.2% increase in FEV1 at 5 min vs predose
23% of patients with 12% increase in FEV1 at 5 min
[59]
Salmeterol 50 mg 60 (95% CI 40, 80) [9]
e 10% decrease of Raw at 15.1 ± 34.5 min [58]
e 4.1% increase in FEV1 at 5 min vs predose
9% of patients with 12% increase in FEV1 at 5 min
[59]
Once-daily LABAs Indacaterol 150 mg 100 (95% CI 70, 130) 7.9% (95% CI 5.4, 10.3) increase at 5 min vs placebo
28% of patients with 12% increase from baseline at
5 min
19% of patients with 12% and >200 mL increase from
baseline at 5 min
[56]
120 (95% CI 100, 140) [60]
110 (95% CI 90, 130) [9]
e FEV1 AUC0e4h: 160 mL increase vs placebo* [10]
Indacaterol 300 mg 120 (95% CI 90, 150) 10.1% (95% CI 7.7, 12.5) increase at 5 min vs placebo
46% of patients with 12% increase from baseline at
5 min
28% of patients with 12% and >200 mL increase from
baseline at 5 min
[56]
130 (95% CI 110, 150) [57]
Vilanterol 25 mg 69 (95% CI 8, 146) [61]
e Time to 12% increase from baseline: 18 min
Time to 100 mL increase in FEV1 from baseline: 6 min
[62]
e 131 mL increase in FEV1 after 15 min vs placebo
Time to100mL increase in FEV1 from baseline: 27min
[63]
e Time to 100 mL increase in FEV1 from baseline 31 min [64]
Olodaterol 5 mg 118* [65]
Twice-daily LAMAs Aclidinium 400 mg e At 15 min: ~70 mL (est.) increase in FEV1 vs placebo* [66]
Once-daily LAMAs Tiotropium 18 mg 45*b At 15 min: 78 mL increase in FEV1 vs placebo*
FEV1 AUC0e4h: 141 mL increase vs placebo*
[67]
60 (95% CI 30, 80)b [60]
e sGaw 0.08 (0, 0.15) 1/kP*s vs placebo at 5 min
FRC 200 mL (95% CI 340, 60) vs placebo at 5 min
[68]
e 39 mL (95% CI 6, 71) from predose at 10 min
12% rise in FEV1 after 79 min (95% CI 18, 140)
[69]
e ~120 mL at 30 min (est.) [70]
e FEV1 AUC0e4h: 140 mL increase vs placebo* [10]
Glycopyrronium 50 mg 93* At 15 min: 144 mL increase in FEV1 vs placebo*
IC 181 mL vs placebo* at 25 min
[71]
87* At 15 min: 143 mL increase in FEV1 vs placebo*
FEV1 AUC0e4h: 197 mL increase vs placebo*
[67]
e FEV1 AUC0e4h: 190 mL increase vs placebo* [10]
Umeclidinium 62.5 mg e Time to increase in FEV1 100 mL above baseline:
56 min FEV1 AUC0e6h: ~135 mL (est.) increase vs
placebo
[64]
LAMA/LABAs QVA149
(indacaterol/glycopyrronium
110/50 mg)
126* FEV1 AUC0e4h: 210 mL increase vs placebo* [72]
130* FEV1 AUC0e4h: 220 mL increase vs placebo* [10]
e sGaw 0.21 (0.14, 0.29) 1/kP*s vs placebo at 5 min
FRC 300 mL (95% CI 440, 160) vs placebo at 5 min
[68]
Umeclidinium/vilanterol
62.5/25 mg
e At 15 min: 112 mL increase in FEV1 vs placebo
Time to increase in FEV1100mL from baseline: 27min
[64]
Values estimated from graphs are denoted by the ‘~’ symbol and qualiﬁed as (est.). FEV1 AUC0e4h, FEV1 averaged over 0e4 h post-dose; FRC, functional residual capacity; FEV1
AUC0e4h, area under the FEV1 curve from 0 to 4 h; IC, inspiratory capacity; Raw, airway resistance; sGaw, speciﬁc airway resistance.
a Statistical signiﬁcance denoted by *p < 0.05 or 95% conﬁdence intervals.
b Open label.
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used as a surrogate measure of hyperinﬂation [3]. Measurements of
airway resistancehavebeen showntocorrelatebetter thanFEV1with
acute bronchodilator-induced changes in dynamic hyperinﬂation,
gas trapping, and dyspnea at rest [53]. Similarly, bronchodilator-
induced improvements in exertional dyspnea have been observed
in the absence of changes in FEV1 [54,55].Tables 3 and 4 compare the onset and duration of bronchodi-
lator effect reported in clinical studies with the various long-acting
agents. Salbutamol is included in Table 3 as an example of a fast-
onset ‘rescue’ bronchodilator.
Among the LABAs, formoterol, indacaterol and olodaterol
appear to share a fast onset of bronchodilator effect (Table 3).
Although the available literature does not fully characterize all the
Table 4
Trough FEV1 (difference vs placebo in mL [95% CI] unless otherwise stated) at 24 h post-dosea after ﬁrst day's dosing, after 12 weeks and at last study day in clinical trials of
long-acting bronchodilators.
Day 1 Week 12 Last time point of study Ref.
Twice-daily LABAs Formoterol 12 mg 110 (90, 130) 70 (40, 100) 50 (10, 90) (wk 52) [57]
Salmeterol 50 mg 120 110 110 mL (wk 26) [9]
e 7.6% from baseline 6.2% from baseline [73]
Twice-daily LAMAs Aclidinium 400 mg Not reported 105 change from
baseline vs placebo
128 ± 22 change from baseline
vs placebo (wk 24)
[74]
Once-daily LABAs Indacaterol 150 mg 130 170 180 (wk 26) [9]
110 (80, 130) 180 (140, 220) 160 (120, 190) (wk 26) [60]
110 (90, 140) 150 (120, 180) 130 (100, 160) (wk 26) [10]
Indacaterol 300 mg 140 (110, 160) 170 (130, 200) 160 (120, 200) (wk 52) [57]
Vilanterol 25 mg Not reported Not reported 30 from randomizationb (wk 52) [75]
~90 (est.) ~90 (est.) 72 (32, 112) (wk 24) [64]
~105 (est.) ~100 (est.) 114 (wk 24) [63]
~105 change
from baseline (est.)
~100 change from
baseline (est.)
121 change from baseline (wk 24) [76]
Olodaterol 5 mg Not reported 91 92 (wk 48) [65]
Not reported 47 68 (wk 48) [65]
Not reported 83 68 (wk 48) [77]
Not reported 59 44 (wk 48) [77]
Once-daily LAMAs Tiotropium 18 mg 100 (70, 120)c 140 (100, 180)c 140 (100, 180)c (wk 26) [60]
83c 83c 89c (wk 52) [67]
120 (90, 140)c 130 (100, 170)c 130 (90, 160)c (wk 26) [10]
Not reported Not reported 120e150 (over 1 year) [70]
Not reported Not reported 137 (wk 24) [8]
Glycopyrronium 50 mg 105 108 113 (wk 26) [71]
91 97 (65, 130) 108 (wk 52) [67]
110 120 120 (80, 150) (wk 26) [10]
Umeclidinium 62.5 mg ~105 (est.) ~135 (est.) 115 (76,155) (wk 24) [64]
LABA/LAMAs QVA149 (indacaterol/
glycopyrronium 110/50 mg
190 (170, 210) 230 (190, 260) 200 (170, 240) L (wk 26) [10]
Not reported 163 189 (wk 52) [78]
Umeclidinium/vilanterol
62.5/25 mg
~155 (est.) ~190 (est.) 167 (128, 207) (wk 24) [64]
~190 (est.) ~185 (est.) 211 (wk 24) [76]
~195 (est.) ~205 (est.) 208 (wk 24) [76]
Values estimated from graphs are denoted by the ‘~’ symbol and qualiﬁed as (est.).
a For the twice-daily agents, 12 h following the second dose of the day.
b ICS withdrawn at randomization.
c Open label.
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of action.
As shown in Table 4, the majority of bronchodilators have an
effect on trough FEV1 after the ﬁrst day's dosing that is very close to
or exceeds the reported minimal clinically important difference of
100 mL [50], the level at which patients may perceive a beneﬁt,
although results at this time point for olodaterol are not reported.
On repeated dosing over several months, both olodaterol and
vilanterol appear to have modest bronchodilator effects when
viewed against results from studies with other long-acting agents.
Comparing effects on trough FEV1 at week 12 and a later (e.g.
week 26 or 52) time point, therewas a loss of effect with formoterol
and a suggestion of a similar phenomenon, or at least inconsistent
long-term effects, with vilanterol and olodaterol. Indacaterol
generally maintained its effect over 1 year (Table 4). This apparent
difference between LABAs may relate to the high intrinsic efﬁcacy
of formoterol, and maybe vilanterol. The process of b2-adrenor-
eceptor desensitization with prolonged exposure to b2-adrenergic
agonist varies between cells, airway smooth muscle being less
prone to the phenomenon than inﬂammatory cells (which may
explain why tachyphylaxis in asthma manifests more commonly as
loss of bronchoprotection rather than loss of bronchodilation)
[21,79]. Tolerance to the typical b2-mediated adverse events of
tachycardia and tremor has been reported [21,80]. The LAMAs
appear to have a consistent effect over time, with glycopyrronium
and tiotropium maintaining trough FEV1 at levels of 100 mL or
more over 1 year. Studies with the newer LAMAs, aclidinium andumeclidinium, currently extend only up to treatment periods of 6
months. The combination LABA/LAMAs have a bronchodilator ef-
fect over time that is approximately 80e90% of the additive effect of
the individual components [10,64].
Based on the data in Tables 3 and 4, indacaterol and glyco-
pyrroniumwould ﬁgure prominently if a bronchodilator were to be
chosen based on its rapid onset of bronchodilation, duration and
magnitude of effect after a single dose, and persistence of bron-
chodilator effect during long-term use. However, whether their
pharmacological advantages translate into superior beneﬁts in
terms of adherence, persistence or other patient perceptions re-
mains to be demonstrated.4. Beneﬁts of fast onset of (bronchodilator) action
It might be expected that fast-onset bronchodilation would
translate into fast relief of dyspnea (as in the case of salbutamol
used as rescue medication). A recent study showed that changes in
airway resistance (not FEV1) 1 h after dosing with indacaterol
300 mg correlated with reductions in hyperinﬂation and gas trap-
ping, and improvement in patient-reported dyspnea [53]. In a study
comparing two fast-acting bronchodilators (formoterol and salbu-
tamol) with the slower-acting salmeterol and oxitropium, the
faster-acting agents induced a greater increase in FEV1 and inspi-
ratory capacity at 30 min post dose [81]. There was a signiﬁcant
correlation between acute bronchodilator effect and symptom
improvement, which was strongest in patients with baseline
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particularly useful in patients who take their treatment regularly
and have relatively stable symptoms. Conversely, it might be of help
in patients with suboptimal adherence to treatment, since
perceived rapid efﬁcacy could reinforce compliance. It could also be
useful in patients with more variable symptoms.
In some patients with COPD, symptoms vary over the day, with
morning considered to be the time when symptoms are more se-
vere [82]. It might be hypothesized that fast-acting agents could be
more effective on these symptoms than thosewith a relatively slow
onset of action, by providing rapid relief of symptoms after morning
dosing [83]. In a 1-week crossover study, a twice-daily ICS/LABA
containing budesonide and formoterol improvedmorning activities
to a greater extent than twice-daily SFC [84] because of the faster
onset of action of formoterol, compared with salmeterol. Similarly,
in a 12-week study, the addition of the budesonide/formoterol
combination to tiotropium resulted in increased FEV1 immediately
post-dose and an improvement in morning symptoms and activ-
ities, compared with tiotropium alone [85]. However, despite their
possible association with poorer health status and more frequentFig. 1. Relationship of changes in dyspnea measured by visual analogue scale with
placebo correction (%) with changes in (A) FEV1 and (B) IC 30 min after bronchodilation
in patients with baseline IC lower than 80% predicted. (A) r ¼ 0.52; r2 ¼ 0.27; p < 0.001;
(B) r ¼ 0.70; r2 ¼ 0.48; p < 0.001. In patients with IC >80% predicted (not shown), the
correlations were r ¼ 0.21; r2 ¼ 0.05; p ¼ 0.26 for FEV1 and r ¼ 0.38; r2 ¼ 0.15; p < 0.05
for IC. FEV1, forced expiratory volume in 1 s; IC, inspiratory capacity; pred, predicted; r,
correlation coefﬁcient; r2, coefﬁcient of determination. Reproduced with permission of
the European Respiratory Society [81]. © European Respiratory Society (2003).exacerbations, it is not known if morning symptoms represent
some kind of phenotype in that such symptoms might be particu-
larly pronounced in some patients independently of overall clinical
severity [86]. The question remains difﬁcult to answer in the
absence of a validated, dedicated assessment tool.
An early (day 1) onset of effect may be useful in the context of a
pulmonary rehabilitation program, where optimizing bronchodi-
lator therapy at the outset has been recommended [87]. In COPD,
exercise is limited by breathing discomfort (dyspnea) before leg
discomfort (peripheral muscle fatigue) [88]. By overcoming dys-
pnea with a bronchodilator, the exercise program could focus on
improving peripheral muscle function [87]. If the commencement
of treatment coincides with the start of the exercise program, there
may be a beneﬁt for patients. Among the once-daily bronchodila-
tors, in studies using submaximal constant load cycle ergometry
testing, both LAMAs glycopyrronium and tiotropiumwere reported
to increase exercise endurance time and exertional dyspnea when
evaluated 2e3 h post-dose on the ﬁrst day of treatment, with
reduction in leg discomfort occurring at a later assessment [88,89].
The LABA indacaterol improved exercise endurance time but not
exertional dyspnea (measured at end of exercise) after the ﬁrst dose
[90].
5. Beneﬁts of sustained duration of effect
5.1. Once-daily vs twice-daily bronchodilators
In terms of standard clinical outcomes (lung function, symptoms
and health status) measured in clinical studies, the once-daily
bronchodilators (LAMA or LABA) have generally performed better
than the twice-daily agents (LABAs), where comparisons have been
performed [8,9,57,91,92] (Table 5). Of note, the 1-year POET study
showed that, in patients with moderate-to-very-severe COPD, the
once-daily LAMA tiotropium was more effective than the twice-
daily LABA salmeterol in preventing exacerbations [93]. This
ﬁnding cannot necessarily be extrapolated to other LABAs.
5.2. Comparison of once-daily bronchodilators with different onsets
of action
Among the once-daily bronchodilators, tiotropium is the most
commonly employed active comparator, as it was the ﬁrst once-
daily inhaled bronchodilator available. In several studies, bron-
chodilators with a fast onset have been compared with tiotropium
(Table 6). As previously shown in Table 3, glycopyrronium has a
faster onset of action than tiotropium. For clinical outcomes
(Table 6), the two LAMAs had similar effects on symptoms, health
status, rescue-medication use and exacerbations. The once-daily
LABA indacaterol performed better than tiotropium for symptoms
and health status [94], but tiotropium was more effective in pre-
venting exacerbations in patients with severe or very severe airﬂow
limitation [95] (Table 6). Indacaterol, may, therefore be more useful
clinically in patients at low risk of exacerbations (the GOLD-deﬁned
patient Groups A and B), although this hypothesis requires formal
testing. It should be noted that the studies summarized in the table
were not necessarily designed or powered to compare the selected
treatments and endpoints shown in the table.
6. Adherence/persistence
Adherence is poor in COPD, typically around 50% in practice
[98e102]. Poor adherence is associated with worse clinical and
economic outcomes [103e107]. Many factors are implicated [102],
including the patient's understanding of the disease and their
Table 5
Once-daily (qd) vs twice-daily (bid): bronchodilation, health status and symptom-based outcomes (measured at end of study unless otherwise stated) in phase III studies of
12 weeks' duration.
Comparison Bronchodilation
(trough FEV1)
Symptoms Health status Rescue use over
study duration
Exacerbations
(moderate/severe)
as efﬁcacy outcome
Ref.
Tiotropium 18 mg qd
(n ¼ 209) vs salmeterol
50 mg bid (n ¼ 213),
24 wks
52 mL (p < 0.01) TDI score difference 0.78
points (p < 0.05); 42% vs
35% responders (NS)
SGRQ total score
difference 1.6 units
(NS); 51% vs 40%
responders (p < 0.05)
Change from
baseline1.45 vs1.44
puffs/d (NS)
NR [8]
Indacaterol 150 mg qd
(n ¼ 333) vs salmeterol
50 mg bid (n¼ 334), 6 mo
70 mL (p < 0.001) TDI score 1.45 vs 0.90
(p < 0.05) (wk 12); 57e61%
vs 49e54% respondersa
(wks 4e26)
5.0 and 4.1 vs
placebo; 53% and 49%
respondersa
Change from
baseline 1.3 vs 1.2
puffs/d (NS)
NR [9]
Indacaterol 150 mg qd
(n ¼ 560) vs salmeterol
50 mg bid (n ¼ 563),
12 wks
60 mL (p < 0.001) TDI score difference 0.63
points (p < 0.001); 69.4% vs
62.7% responders (p < 0.05)
NR Difference 0.18 puffs/
d (p < 0.05)
NR [91]
Indacaterol 300 mg qd
(n ¼ 437) vs formoterol
12 mg bid (n ¼ 435), 1 yr
110 mL (p  0.001) TDI score difference 0.29
points (NS)
SGRQ score
difference 0.7 units
(NS)
Difference 0.34 puffs/
d (p < 0.05)
0.60 vs 0.56 per year
(NS); 32.8 vs 31.5% of
patients (NS)
[57]
Tiotropium 18 mg qd
(n ¼ 158) vs aclidinium
400 mg bid (n ¼ 171),
6 wks
Difference in change
from baseline 38 mL
(NS)
E-RS total score 0.7 (NS) NR Difference 0.7%
rescue-free days (NS)
NR [66]
Tiotropium 18 mg qd
(n ¼ 221) vs formoterol
12 mg bid (n¼ 210), 6 mo
NR Total daily symptom score
4.50 vs 4.29 (median)a,b
SGRQ score differences
vs placebo: 2 vs 3
units
0.67 vs 1.30 puffs/
d (median)a
10.4 vs 8.1% of patients
(moderate) (p < 0.05,
formoterol vs placebo);
2.3% vs 0.5% (severe)
[92]
Tiotropium 18 mg qd
(n ¼ 3707) vs salmeterol
50 mg bid (n¼ 3669), 1 yr
NR NR NR NR 17% reduction in risk
(p < 0.001); rate ratio
0.89 (95% CI 0.83,
0.960); p ¼ 0.002
[93]
Responders are those patients with an improvement from baseline equal to or exceeding the minimum clinically important difference (TDI 1 point; SGRQ  4 units). E-RS,
EXAcerbations of Chronic pulmonary disease Tool (EXACT)-Respiratory Symptoms; NR, not reported; NS, not signiﬁcantly different; SGRQ, St George's Respiratory Ques-
tionnaire; TDI, transition dyspnea index.
a Statistical comparison not reported.
b Total daily symptom score ¼ sum of scores for breathlessness, cough, wheeze, amount and color of sputum, each scored on a 0e3 scale where 0 ¼ no symptoms.
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[98,102,112e114].
The relative simplicity and convenience of once-daily dosing
(compared with multiple daily dosing) may encourage patients'
adherence and persistence with their long-term medications. InTable 6
Selected treatment comparisons (at study endpoint) between glycopyrronium or indaca
Comparison Symptoms (TDI total
score, points)
Health status (SGRQ total
score, units)
Glycopyrronium vs
tiotropium open
label, 52 wks
0.1 (NS) 0.5 (NS)
Glycopyrronium vs
tiotropium blinded,
12 wks
0.2 (NS) 0.7 (NS)
Glycopyrronium vs
tiotropium, 26 wks
Differences from
placebo: 0.9 vs 0.6 (NS)
Differences from
placebo: 1.8 vs 0.9 (NS
Glycopyrronium vs
tiotropium, 62 wksa
N/A 0.6 (NS)b
Indacaterol 150 mg and
300 mg vs tiotropium
18 mg od (open
label), 26 wks
Differences from
placebo: 1.0 and 1.2 vs
0.9 (NS)
Differences from
placebo: 3.3* and 2.4
vs 1.0 (*p < 0.05 vs
tiotropium; NS for 300 mg
Indacaterol 150 mg vs
tiotropium 18 mg od
(blinded), 12 wks
0.6 (p < 0.001) 2.1 (p < 0.001)
Indacaterol 150 mg vs
tiotropium (blinded),
52 wksa
0.3 (p ¼ 0.02) 0.2 (NS)
N/A ¼ not applicable (not analyzed or not reported); NS ¼ not signiﬁcant; TDI ¼ transit
a Study conducted among patients with severe or very severe COPD.
b Unpublished data (supplied by study sponsors on request).one retrospective study of a claims database, adherence was
strongly correlated with dosing frequency, with 43.3, 37.0, 30.2 and
23.0 percentage days covered for patient cohorts receiving once,
twice, three times or four times daily treatment [112]. Similarly, in a
study to determine the effect of dosing frequency of mometasoneterol vs tiotropium for health status and symptom-based outcomes.
Rescue use over study
duration, puffs/day
Moderate/severe exacerbations,
rate ratio (95% CI)
Ref.
0.3 (NS) 0.82 (0.61, 1.09) (NS)b [67]
0 (NS) 1.10 (0.62, 1.93) (NS) [96]
)
Differences from
placebo: 0.3 vs 0.4
(NS)
N/A [10]
N/A 1.03 (0.91, 1.16) (NS)\ [97]
)
Changes from
baseline: 1.5*
and 1.6* vs 1.0
(*p < 0.05 vs
tiotropium; NS for
300 mg)
0.96 (0.64,1.43) and
1.06 (0.71,1.57) (NS)b
[60]
0.5 (p < 0.001) N/A [94]
0.6 (p < 0.001) 1.24 (p < 0.001) [95]
ion dyspnea index; SGRQ ¼ St George's Respiratory Questionnaire.
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rates were greater with a once-daily regimen compared with twice
daily [115]. In a survey of patients with COPD, those who reported
low adherence were more likely to prefer once-daily medication
thanwere those with good adherence; this preferencewas found to
be associated with a high self-perceived need for controller medi-
cation [116], indicating the importance of tailoring treatment de-
cisions to the individual patient's needs and preferences.
Persistence with inhaled medications for COPD is also directly
related to the daily frequency of administration [117].
A fast onset may also be useful in the case of missed doses, a
form of non-adherence that is common in COPD [118,101]. Adher-
ence is reported to be lower for medications that do not have an
immediate effect on symptoms [102].
7. Remaining questions and future research
It is still not ﬁrmly established whether long-acting broncho-
dilators should be started in obstructed patients in the absence of
symptoms, and whether it is better to start with a b2-adrenergic
agonist or an antimuscarinic agent in patients with mild/moderate
stable COPD. Thus, in almost all guidelines, no distinction is made
as to which class of bronchodilators should be considered ﬁrst;
rather, they only recommend the use of long-acting agents. Simi-
larly, the guidelines do not advise on whether once-daily or twice-
daily dosing is preferable, although theweight of evidence supports
the better clinical efﬁcacy of the once-daily agents. Moreover,
although LABA/LAMA combinations are recommended as an option
for patients with increased symptoms and for those at higher risk of
exacerbations [1], there is currently no real guidance onwhen such
treatments should be applied in preference to alternative treat-
ments [119]. In any case, it is likely that the lack of indication of
bronchodilators class that should be used as ﬁrst choice is due to
the fact that the putative superiority of one class over another
documented by some randomized clinical trials was based on only
one speciﬁc outcome or method of research, the results of which
might not be generalizable [119].
Given the many different variables affecting adherence, it is
probably an oversimpliﬁcation to suppose that using a highly efﬁ-
cacious treatment will in itself lead to improved adherence. Indeed,
in the TORCH study, the association between increased adherence
and improved mortality and reduction in hospital admission was
independent of study treatment. The effect of treatment was more
pronounced in patients with good adherence than in those with
poor adherence, rather than adherence being better in patients
receiving the most effective treatment [103].
The relationship between a simple dosing regimen and
improved adherence has been reasonably well studied in asthma
and COPD [115,116,120], and using a medication dosed once daily
should help in addressing the problem of non-adherence. A pa-
tient's perception of beneﬁt when restarting a medication or
changing to a faster-onset one may be useful to the treating
physician in improving the management of a poorly adherent pa-
tient. However, further research is warranted to explore the asso-
ciation between a fast onset and adherence, especially in terms of
how best to measure fast onset, e.g. patients' perception, subjective
experience and clinical effect. Many of these concepts are not easily
investigated within the constraints of a randomized, controlled
trial, and a more pragmatic approach using observational research
will be required.
There are also challenges in terms of how best to deﬁne and
measure adherence. Research techniques to address adherence
with inhaled medication include canister weighing and electronic
monitoring of inhaler actuation. Self-reporting is a simple and easy
way to assess adherence and is useful in identifying patients'reasons for non-adherence [121], although the accuracy of this
method has been questioned [122]. Numbers of ﬁlled prescriptions
are used as an indicator of adherence/persistence, but again may
not reﬂect medications taken. Inhalers can now be ﬁtted with
electronic monitoring devices that can allow clinicians to track
adherence and/or trigger reminders of missed doses direct to the
patient. This type of monitoring could help identify barriers to
adherence and provide a basis for subsequent discussions with
non-adherent patients [123].
In 2008, Bourbeau & Bartlett identiﬁed a need to develop
effective treatments for COPD with simpliﬁed treatment regimens
(infrequent dosing, simple delivery), rapid onset of action and du-
rable effect, which would increase the probability of patient
adherence [102]. Among the various effective agents available to
prescribers today, choosing a once-daily bronchodilator with a fast
onset of action (or combination thereof) provides an ideal phar-
macodynamic proﬁle that may encourage patient adherence. Use of
combination inhalers may improve adherence if it reduces the daily
number of medications [101]. Effecting a behavioral change in non-
adherent patients requires patient-centered care characterized by
concordance (i.e. shared decision-making about therapy by doctors
and patients). Effort should be focused on patient education
regarding the importance of regular administration and exploring
patients' perceptions of their burden of therapy and their goals and
expectations from COPD treatment.
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